NCT05918523 A Long-Term Follow-Up Study of Participants Exposed to REACT
| NCT ID | NCT05918523 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Prokidney |
| Condition | Diabetic Kidney Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-12-11 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2023-12-11 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Eligibility Criteria
Inclusion Criteria: * The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol. Exclusion Criteria: * The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.
Contact & Investigator
Study Director
STUDY DIRECTOR
Prokidney
Frequently Asked Questions
Who can join the NCT05918523 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 80 Years, studying Diabetic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05918523 currently recruiting?
Yes, NCT05918523 is actively recruiting participants. Contact the research team at info@prokidney.com for enrollment information.
Where is the NCT05918523 trial being conducted?
This trial is being conducted at Meridian, United States.
Who is sponsoring the NCT05918523 clinical trial?
NCT05918523 is sponsored by Prokidney. The principal investigator is Study Director at Prokidney. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.